C360R

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card

Cysteine → Arginine at position 360 · Transmembrane helix 2 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type C360 — hydrogen bond to V364

Fullscreen ↗

DynaMut2 mutant · C360R

Mutant R360 — hydrogen bond to V633 lost (2 contacts lost)

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost14 gained9 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	S356	S356	Preserved
Hydrogen bond	—	M357	Gained
Hydrogen bond	K363	K363	Preserved
Hydrogen bond	V364	V364	Preserved
Hydrogen bond	—	P404	Gained
Hydrogen bond	—	S411	Gained
Hydrogen bond	V633	—	Lost
Polar contact	S356	S356	Preserved
Polar contact	M357	M357	Preserved
Polar contact	V358	—	Lost
Polar contact	—	L362	Gained
Polar contact	K363	K363	Preserved
Polar contact	V364	V364	Preserved
Polar contact	—	P404	Gained
Polar contact	—	H407	Gained
Polar contact	—	S411	Gained
Carbonyl	—	K363	Gained
Van der Waals	—	S356	Gained
Van der Waals	—	M357	Gained
Van der Waals	H407	H407	Preserved
Van der Waals	—	F408	Gained
Hydrophobic	—	K363	Gained
Hydrophobic	—	V364	Gained
Hydrophobic	—	P404	Gained
Hydrophobic	F408	F408	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-1.42kcal/mol

Destabilising — moderate

AlphaMissense

0.994

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, multiple submitters, no conflicts

Associated conditions—

Population frequency (gnomAD v4)Ultra-rare · AF 0.000068%

cDNA changec.1078T>C

ClinVar accessionVCV002790627

Last evaluated2024/02/09 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — C360R Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Cysteine → Arginine at position 360. Transmembrane helix 2. ClinVar Uncertain significance, AlphaMissense 0.994, DynaMut2 ΔΔG -1.42 kcal/mol (destabilising).

Identity

Field	Value
Variant	C360R (p.Cysteine360Arginine)
DNA change	c.1078T>C
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV002790627
Amino acid change	Cysteine (C) → Arginine (R)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 360	90.12 — well-folded
Domain	Transmembrane helix 2
Position context	Inside Transmembrane helix 2 · position 360 is bilayer-embedded
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 360 sits in a transmembrane helix (Transmembrane helix 2). Wolframin has eleven such helices anchoring it in the ER membrane; substitutions inside the bilayer-embedded segments can disrupt helix packing, lipid contacts, and the overall ER topology of the protein. The wild-type residue is thiol (cysteine — disulfide-capable, free -SH); the mutant is positively charged (arginine — guanidinium, strong H-bond donor). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.9937
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-1.42 (Destabilising)
Job ID	178092137123
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092137123

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2024/02/09 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	C360R is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.42 < 2 kcal/mol (fold intact) + AlphaMissense 0.994 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.42 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.994. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
C360R_molstar_viewer.html — interactive 3D viewer (auto-highlights position 360 with ball-and-stick + neighbors within 5Å)
C360R_variant_card.md — this card (source of truth)
C360R_variant_card.html — styled printable card
C360R_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
C360R_wildtype_interactions.pse / C360R_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the C360R PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download C360R PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.